FIDO study shows greater risk for vision loss from undertreatment of wet AMD at 10 years

CHICAGO — Undertreating patients with neovascular age-related macular degeneration posed a greater risk for vision loss compared with patients treated continuously with anti-VEGF agents over 10 years, according to a speaker here.
“Continuous mixed interval dosing can provide long-term stability of early vision gains, which is especially important with longer-acting drugs, port delivery systems and gene therapy on the horizon,” Ivan J. Suñer, MD, MBA, said at the American Society of Retina Specialists meeting.
The FIDO study included 145 patients with wet AMD who

Full Story →